US2023383286A1PendingUtilityA1
Phage engineering: protection by circularized intermediate
Assignee: CHARLES STARK DRAPER LABORATORY INCPriority: Jun 1, 2017Filed: Nov 14, 2022Published: Nov 30, 2023
Est. expiryJun 1, 2037(~10.8 yrs left)· nominal 20-yr term from priority
C12N 2310/20C12N 9/222C12N 15/1072C12N 15/86C12N 15/902C12N 7/00C12N 9/22C12N 15/1037C12N 15/1058C12N 15/1086C12N 15/113C12N 2795/10243
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides methods of generating recombinant bacteriophage genomes. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a linear bacteriophage DNA genome, and isolating recombinant bacteriophages that express the heterologous nucleic acid sequence.
Claims
exact text as granted — not AI-modified1 . A kit comprising (a) one or more labeled vials containing a plurality of linear bacteriophage DNA genomes, (b) at least one CRISPR enzyme, (c) a recombination system, and (d) at least one exonuclease, and optionally instructions for use.
2 . The kit of claim 1 , wherein the at least one exonuclease is selected from the group consisting of Lambda exonuclease, Exonuclease III, RecBCD, Exonuclease VIII truncated, T5 exonuclease, and T7 exonuclease.
3 . The kit of claim 1 , wherein the recombination system comprises a 5′-3′ exonuclease, a DNA polymerase, and a DNA ligase.
4 . The kit of claim 1 , wherein the at least one CRISPR enzyme is a Cas protein selected from the group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cash, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4.
5 . The kit of claim 1 , wherein the recombination system comprises a 3′-5′ exonuclease, a DNA polymerase, and a DNA ligase.
6 . The kit of claim 1 , wherein the plurality of linear bacteriophage DNA genomes correspond to a bacteriophage family or order selected from the group consisting of Myoviridae, Styloviridae, Siphoviridae, Pedoviridae, Tectiviridae, Leviviridae, Podoviridae, and Plasmaviridae.
7 . The kit of claim 1 , wherein the plurality of linear bacteriophage DNA genomes are derived from one or more bacteriophage genuses (or genera) selected from the group consisting of T7-like phage, phiKMV-like phage, LUZ24-like phage, phiKZ-like phage, PB1-like phage, Felix-O1-like phage, T4-like phage, phi92-like phage, rV5-like phage, SP6-like phage, N4-like phage, phiEco32-like phage, T5-like phage, KP34-like phage, KP15-like phage, GAP227-like phage, AP22-like phage, phiFel-like phage, Sap6-like phage, Silvia-like phage, Kay-like phage, Twort-like phage, P68-like phage, and phiETA-like phage.
8 . The kit of claim 4 , wherein the at least one CRISPR enzyme is coupled to a sgRNA.
9 . The kit of claim 8 , wherein the sgRNA has the sequence of SEQ ID NO:2 or SEQ ID NO:3.
10 . The kit of claim 1 , further comprising a heterologous nucleic acid.
11 . The kit of claim 10 , wherein the heterologous nucleic acid comprises an open reading frame that encodes a bioluminescent protein, a fluorescent protein, a chemiluminescent protein, or any combination thereof.
12 . The kit of claim 11 , wherein the bioluminescent protein is selected from the group consisting of Aequorin, firefly luciferase, Renilla luciferase, red luciferase, luxAB, and nanoluciferase.
13 . The kit of claim 11 , wherein the fluorescent protein is selected from the group consisting of blue/UV fluorescent proteins (for example, TagBFP, Azurite, EBFP2, mKalama1, Sirius, Sapphire, and T-Sapphire), cyan fluorescent proteins (for example, ECFP, Cerulean, SCFP3A, mTurquoise, monomeric Midoriishi-Cyan, TagCFP, and mTFP1), green fluorescent proteins (for example, EGFP, Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, and mWasabi), yellow fluorescent proteins (for example, EYFP, Citrine, Venus, SYFP2, and TagYFP), orange fluorescent proteins (for example, Monomeric Kusabira-Orange, mKOK, mKO2, mOrange, and mOrange2), red fluorescent proteins (for example, mRaspberry, mCherry, dsRed, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, and mRuby), far-red fluorescent proteins (for example, mPlum, HcRed-Tandem, mKate2, mNeptune, and NirFP), near-IR fluorescent proteins (for example, TagRFP657, IFP1.4, and iRFP), long stokes-shift proteins (for example, mKeima Red, LSS-mKate1, and LSS-mKate2), photoactivatable fluorescent proteins (for example, PA-GFP, PAmCherryl, and PATagRFP), photoconvertible fluorescent proteins (for example, Kaede (green), Kaede (red), KikGR1 (green), KikGR1 (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), PSmOrange, and PSmOrange), fluorescein, rhodamine, and photoswitchable fluorescent proteins (for example, Dronpa).
14 . The kit of claim 11 , wherein the chemiluminescent protein is selected from the group consisting of β-galactosidase, horseradish peroxidase (HRP), and alkaline phosphatase.
15 . The kit of claim 11 , wherein the heterologous nucleic acid comprises an epitope that can be detected with an antibody or other binding molecule.
16 . The kit of claim 11 , wherein the heterologous nucleic acid comprises a polypeptide tag sequence selected from among poly-histidine, FLAG, and Glutathione S-transferase (GST).
17 . The kit of claim 11 , wherein the heterologous nucleic acid sequence comprises a biotin binding protein.
18 . The kit of claim 17 , wherein the biotin binding protein is avidin, streptavidin, or neutrAvidin.
19 . The kit of claim 17 , wherein the biotin binding protein is detected using a biotin molecule conjugated to an enzyme or an antibody.
20 . The kit of claim 19 , wherein the enzyme is β-galactosidase, horseradish peroxidase (HRP), or alkaline phosphatase.Join the waitlist — get patent alerts
Track US2023383286A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.